Literature DB >> 17639646

Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs.

Lawrence S Brown1, Steven Kritz, R Jeffrey Goldsmith, Edmund J Bini, Jim Robinson, Donald Alderson, John Rotrosen.   

Abstract

The National Drug Abuse Treatment Clinical Trials Network conducted this study to determine the availability of and factors associated with infection-related health services in substance abuse treatment settings. In a cross-sectional descriptive design, state policies, reimbursement for providers, state level of priority, and treatment program characteristics were studied via written surveys of administrators of substance abuse treatment programs and of state health and substance abuse departments. Data from health departments and substance abuse agencies of 48 states and from 269 substance abuse treatment programs revealed that human immunodeficiency virus/acquired immunodeficiency syndrome-related services are more frequent than hepatitis C virus or sexually transmitted infection-related services, and that nonmedical services are more frequent than medical services. While the availability of infection-related health services is associated with medical staffing patterns, addiction pharmacotherapy services, and state priorities, reimbursement was the most significant determining factor. These findings suggest that greater funding of these health services in substance abuse treatment settings, facilitated by supportive state policies, represents an effective response to the excess morbidity and mortality of these substance use-related infections.

Entities:  

Mesh:

Year:  2007        PMID: 17639646      PMCID: PMC1888517          DOI: 10.1177/003335490712200404

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  28 in total

1.  Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.

Authors:  J Lorvick; A H Kral; K Seal; L Gee; B R Edlin
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.

Authors:  Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

Review 3.  Drug abuse treatment as an HIV prevention strategy: a review.

Authors:  J L Sorensen; A L Copeland
Journal:  Drug Alcohol Depend       Date:  2000-04-01       Impact factor: 4.492

Review 4.  Extending the evidence hierarchy to enhance evidence-based practice for substance use disorders.

Authors:  Jalie A Tucker; David L Roth
Journal:  Addiction       Date:  2006-07       Impact factor: 6.526

5.  Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy.

Authors:  K E Poundstone; R E Chaisson; R D Moore
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

6.  Treatment Outcome Prospective Study (TOPS): client characteristics and behaviors before, during, and after treatment.

Authors:  R L Hubbard; J V Rachal; S G Craddock; E R Cavanaugh
Journal:  NIDA Res Monogr       Date:  1984

7.  A nationwide survey of hepatitis C services provided by drug treatment programs.

Authors:  Shiela M Strauss; Gregory P Falkin; Zdravko Vassilev; Don C Des Jarlais; Janetta Astone
Journal:  J Subst Abuse Treat       Date:  2002-03

8.  Substance abuse and HIV infection.

Authors:  Henry Francis
Journal:  Top HIV Med       Date:  2003 Jan-Feb

9.  Differences in HIV disease progression by injecting drug use in HIV-infected persons in care.

Authors:  Richard D Moore; Jeanne C Keruly; Richard E Chaisson
Journal:  J Acquir Immune Defic Syndr       Date:  2004-01-01       Impact factor: 3.731

10.  Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2002-05-10
View more
  24 in total

1.  Substance abuse treatment as HIV prevention: more questions than answers.

Authors:  Lawrence S Brown; Steven Kritz; Edmund J Bini; Ben Louie; Jim Robinson; Donald Alderson; John Rotrosen
Journal:  J Natl Med Assoc       Date:  2010-12       Impact factor: 1.798

2.  Adoption and utilization of sexually transmitted infections testing in outpatient substance abuse treatment facilities serving high risk populations in the U.S.

Authors:  Erick G Guerrero; Julie A Cederbaum
Journal:  Int J Drug Policy       Date:  2010-10-20

3.  States and substance abuse treatment programs: funding and guidelines for infection-related services.

Authors:  Steven Kritz; Lawrence S Brown; R Jeffrey Goldsmith; Edmund J Bini; Jim Robinson; Donald Alderson; Patricia Novo; John Rotrosen
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

4.  Directly observed antiretroviral therapy eliminates adverse effects of active drug use on adherence.

Authors:  Shadi Nahvi; Alain H Litwin; Moonseong Heo; Karina M Berg; Xuan Li; Julia H Arnsten
Journal:  Drug Alcohol Depend       Date:  2011-08-31       Impact factor: 4.492

5.  Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians.

Authors:  E Jennifer Edelman; An T Dinh; Brent A Moore; Richard S Schottenfeld; David A Fiellin; Lynn E Sullivan
Journal:  J Addict Med       Date:  2012-06       Impact factor: 3.702

6.  Community Providers' Impression of HIV Prevention Intervention Research in NIDA's Clinical Trials Network.

Authors:  Aimee N C Campbell; Bryan Hartzler; Mary Hatch-Maillette; Donald A Calsyn; Gloria M Miele; Susan Tross
Journal:  J Drug Issues       Date:  2011

7.  Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.

Authors:  Jemima A Frimpong; Thomas D'Aunno; Lan Jiang
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

8.  Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.

Authors:  Edmund J Bini; Steven Kritz; Lawrence S Brown; Jim Robinson; Donald Calsyn; Don Alderson; Kathlene Tracy; Patrick McAuliffe; Cheryl Smith; John Rotrosen
Journal:  J Subst Abuse Treat       Date:  2011-10-27

Review 9.  Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

Authors:  E Jennifer Edelman; David A Fiellin
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

10.  An HIV prevention intervention for ethnically diverse men in substance abuse treatment: pilot study findings.

Authors:  Donald A Calsyn; A Kathleen Burlew; Mary A Hatch-Maillette; Blair Beadnell; Lynette Wright; Jerika Wilson
Journal:  Am J Public Health       Date:  2013-03-14       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.